EMG
SVA

Ellington Management Group’s Sinovac Biotech, Ltd SVA Stock Holding History

Ellington Management Group’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-43,000
Closed -$310K – 840
2014
Q1 		$310K Buy
43,000
+9,200
+27% +$60.9K 0.09% 350
2013
Q4 		$207K Sell
33,800
-8,600
-20% -$51.8K 0.07% 452
2013
Q3 		$254K Buy
+42,400
New +$203K 0.05% 575

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ellington Management Group's SVA Position: Q2 2014 in Review

Ellington Management Group sold out of Sinovac Biotech, Ltd (SVA) in Q2 2014, closing a stake of 43,000 shares — an estimated $310K sold.

Ellington Management Group first reported a position in SVA in Q3 2013 and held it in 3 quarters. The position peaked at $310K in Q1 2014. 50 funds tracked by Wall St. Rank hold SVA as of Q2 2014.

  • Ellington Management Group reported no remaining Sinovac Biotech, Ltd position as of Q2 2014 after selling out during the quarter.
  • Ellington Management Group sold 43,000 Sinovac Biotech, Ltd shares in Q2 2014, an estimated $310K.
  • Ellington Management Group first reported a position in Sinovac Biotech, Ltd in Q3 2013 and held it in 3 quarters.
  • Ellington Management Group's Sinovac Biotech, Ltd position peaked at $310K in Q1 2014.
  • 50 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2014.

Based on Ellington Management Group's 13F filing for Q2 2014, filed 14 Aug 2014.